• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Midodrine     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substancePill (pharmacy)yago:WikicatAminesyago:WikicatCardiacStimulantsyago:WikicatMolecularFormulasyago:Abstraction100002137yago:Acetamide114711197yago:AliphaticCompound114601294yago:Amide114724264yago:Amine114739004yago:Chemical114806838yago:Cognition100023271yago:Communication100033020yago:Compound114818238yago:Element114840755yago:Formula106816935yago:Information105816287yago:Material114580897yago:Matter100020827yago:Message106598915yago:MethaneSeries114951377yago:MolecularFormula106817173yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:PsychologicalFeature100023100yago:Quintessence114847103yago:Relation100031921drugyago:Statement106722453yago:Stimulation105827684yago:Substance100019613yago:WikicatAcetamidesyago:WikicatPhenolEthersumbel-rc:DrugProduct New Facet based on Instances of this Class

Midodrine is a vasopressor/antihypotensive agent (it raises the blood pressure). Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension. In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, failed to complete required studies after the medicine reached the market. In September 2010, the FDA reversed its decision to remove midodrine from the market and allowed it to remain available to patients while Shire plc collected further data regarding the efficacy and safety of the drug. Shire announced on September 22, 2011, that it was withdrawing completely from supplying midodrine and leaving it to several generics to supply the drug.